Skip to content

OSA screening in COPD

The utility of a clinical algorithm for diagnosing Obstructive Sleep Apnoea (OSA) in symptomatic patients with Chronic Obstructive Pulmonary Disease (COPD)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12607000288426
Enrollment
360
Registered
2007-05-31
Start date
2007-03-15
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

At enrolment eligibility will be confirmed. Subjects will answer questionnaires; have anthropometric measures taken and upper airway function and lung function assessed. All patients will undergo home testing with a diagnostic device for three nights and have an in laboratory sleep study in random order. All tests will be performed within a 4 week period. The results will not be communicated to the participant or the treating physicians until all components have been performed. The participants will then be referred to a sleep specialist to have the results of the polysomnogram discussed, and appropriate management instituted outside of the study, as dictated by usual clinical practice.

Interventions

Questionnaires, biometric data, upper airway function (using the Forced Oscillation Technique) and lung function (using standard pre and post bronchodilator spirometry) will be administered over 30 minutes by research staff upon enrolment. Subjects will then be allocated to receive both the single channel home based sleep apnoea monitoring device (Flow Wizard, DiagnoseIT, Australia) for three nights at home and in hospital polysomnography for one night in random order. Subjects will receive both

Questionnaires, biometric data, upper airway function (using the Forced Oscillation Technique) and lung function (using standard pre and post bronchodilator spirometry) will be administered over 30 minutes by research staff upon enrolment. Subjects will then be allocated to receive both the single channel home based sleep apnoea monitoring device (Flow Wizard, DiagnoseIT, Australia) for three nights at home and in hospital polysomnography for one night in random order. Subjects will receive both the in hospital polysomnography and home testing within a four week period. The wash out period is 24hours.

Sponsors

Woolcock Institute of Medical Research
Lead SponsorOther

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Diagnosis
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Healthy volunteers
No

Inclusion criteria

Group 1 (Control group): symptoms of sleep apnoea (including snoring, choking, witnessed apneas and daytime sleepiness) and/or co morbidities including obesity, hypertension and the metabolic syndrome that are non smokers with < 5 pack year history. Group 2 COPD patients who are smokers or ex smokers with > 10 pack year history of smoking and symptoms of OSA, and/or co morbidities including obesity, hypertension and the metabolic syndrome, are able to give informed consent.

Exclusion criteria

Inability to comply with procedures, previous diagnosis of other respiratory and/or sleep disorders, and current treatment with continuous positive airways pressure, a tracheostomy or home oxygen as well as poorly controlled other medical conditions.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026